Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-02-21

FDA Approved: DOXAZOSIN — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for doxazosin mesylate (doxazosin) submitted by Teva Pharmaceuticals USA, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Doxazosin (doxazosin)

Snippet

SUPPL AP for DOXAZOSIN (DOXAZOSIN MESYLATE)